Biochemical analysis of CTLA-4 immunoreactive material from human blood

BMC Immunology

Volumn 10, Issue , 2009, Pages 51-

  Tector, Matt ^a   Khatri, Bhupendra O ^b   Kozinski, Karen ^a   Dennert, Kate ^a   Oaks, Martin K ^a  

^a ST LUKE S MEDICAL CENTER   (United States)

^b Center for Neurological Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOGLOBULIN; LIGAND;

ARTICLE; BIOCHEMISTRY; GEL FILTRATION; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; LIGAND BINDING; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; BLOOD PROTEINS; CHEMICAL FRACTIONATION; HUMANS; IMMUNOMODULATION; MASS SPECTROMETRY; MYASTHENIA GRAVIS; PROTEIN BINDING;

EID: 70449398372     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-10-51     Document Type: Article

References (32)

1. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006, 24:65-97. 10.1146/annurev.immunol.24.021605.090535, 16551244.
2. Perkins D. Regulation of CTLA-4 expression during T cell activation. J Immunol 1996, 156(11):4154-9.
3. Kuiper HM. Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 1995, 155(4):1776-83.
4. Linsley PS. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991, 173(3):721-30. 10.1084/jem.173.3.721, 2118836, 1847722.
5. Linsley PS. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174(3):561-9. 10.1084/jem.174.3.561, 2118936, 1714933.
6. Calvo CR, Amsen D, Kruisbeek AM. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med 1997, 186(10):1645-53. 10.1084/jem.186.10.1645, 2199134, 9362525.
7. Lee KM. Molecular basis of T cell inactivation by CTLA-4. Science 1998, 282(5397):2263-6. 10.1126/science.282.5397.2263, 9856951.
8. Schneider H. CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci USA 2005, 102(36):12861-6. 10.1073/pnas.0505802102, 1192824,1192824, 16126897.
9. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 1998, 188(10):1849-57. 10.1084/jem.188.10.1849, 2212416, 9815262.
10. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3(7):611-8. 10.1038/ni0702-611, 12087419.
11. Grohmann U. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3(11):1097-101. 10.1038/ni846, 12368911.
12. Fallarino F. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4(12):1206-12. 10.1038/ni1003, 14578884.
13. Karandikar NJ. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996, 184(2):783-8. 10.1084/jem.184.2.783, 2192746, 8760834.
14. Magistrelli G. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999, 29(11):3596-602. 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y, 10556814.
15. Oaks MK. A native soluble form of CTLA-4. Cell Immunol 2000, 201(2):144-53. 10.1006/cimm.2000.1649, 10831323.
16. Huurman VA. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 2007, 150(3):487-93. 2219382, 17924973.
17. Saverino D. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007, 123(2):190-8. 10.1016/j.clim.2007.01.003, 17321799.
18. Ueda H. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423(6939):506-11. 10.1038/nature01621, 12724780.
19. Vijayakrishnan L. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004, 20(5):563-75. 10.1016/S1074-7613(04)00110-4, 15142525.
20. Waterhouse P. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-8. 10.1126/science.270.5238.985, 7481803.
21. Tivol EA. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-7. 10.1016/1074-7613(95)90125-6, 7584144.
22. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000, 164(10):5015-8.
23. Wong CK. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44(8):989-94. 10.1093/rheumatology/keh663, 15870153.
24. Liu MF. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004, 59(2):198-202. 10.1111/j.0300-9475.2004.01370.x, 14871297.
25. Sato S. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004, 43(10):1261-6. 10.1093/rheumatology/keh303, 15266059.
26. Ip WK. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int Arch Allergy Immunol 2005, 137(1):45-52. 10.1159/000084612, 15785081.
27. Wong CK. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 2005, 141(1):122-9. 10.1111/j.1365-2249.2005.02815.x, 1809415, 15958078.
28. Luszczek W. CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. Int J Immunogenet 2006, 33(3):217-24. 10.1111/j.1744-313X.2006.00600.x, 16712655.
29. Chinnasamy D. A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4. Cancer Immunol Immunother 2006, 55(12):1504-14. 10.1007/s00262-006-0153-7, 16612600.
30. She JX. Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes. Proc Natl Acad Sci USA 1999, 96(14):8116-9. 10.1073/pnas.96.14.8116, 22197, 10393957.
31. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988, 34(1):27-33.
32. Berry A, Tector M, Oaks MK. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. J Negat Results Biomed 2008, 7:8. 10.1186/1477-5751-7-8, 2596078, 19014504.